Hydroxyurea Medac (Hydroxycarbamide)

Hydroxycarbamide (hydroxyurea) works by inhibiting the enzyme ribonucleotide reductase, which is essential for making deoxyribonucleotides—the building blocks of DNA. This inhibition lowers DNA synthesis, slowing the proliferation of rapidly dividing cells such as malignant leukocytes or abnormal red blood cells.

The dosage of Hydroxyurea Medac is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and blood‑count response. Patients should follow the dose and schedule provided by their healthcare professional.

Hydroxyurea is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless no safer alternative exists and the benefits outweigh the risks. The drug is also excreted in breast milk, so breastfeeding is not recommended while taking Hydroxyurea.

To order Hydroxyurea Medac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details and any required import documentation.

Hydroxyurea is the only disease‑modifying oral therapy approved for sickle cell disease, whereas alternatives such as blood transfusions or newer gene‑editing approaches are more invasive or still investigational. Hydroxyurea reduces painful crises and transfusion needs, offering a convenient oral option with a well‑characterized safety profile.

Hydroxyurea Medac should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in a bathroom or near a heat source, and keep the container tightly closed when not in use.

Hydroxyurea Medac is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless the prescriber advises otherwise. Dosing times are typically consistent each day to maintain stable drug levels.

The most serious risks include severe bone‑marrow suppression leading to infections or bleeding, renal or hepatic toxicity, and teratogenic effects that can harm a developing fetus. Patients should be monitored regularly for blood‑count changes and organ function, and pregnancy must be avoided.

Hydroxyurea Medac is contraindicated in patients with known hypersensitivity to hydroxyurea, those who are pregnant without a compelling indication, and individuals with severe bone‑marrow failure not related to the target disease. Caution is also advised for patients with significant renal or hepatic impairment.